Cogent Biosciences Inc (COGT)

$16.20 +1.07 (7.07%)
Market Cap 1.72B
Revenue (ttm) 0.00
Net Income (ttm) -255.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,449,300
Avg Vol 1,916,380
Day's Range N/A - N/A
Shares Out 113.86M
Stochastic %K 32%
Beta 0.30
Analysts Strong Sell
Price Target $21.85

Company Profile

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The c...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 945 5576
Address:
275 Wyman Street, 3rd Floor, Waltham, United States
HahaYouSUCK
HahaYouSUCK Oct. 27 at 8:35 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 27 at 1:37 PM
$COGT don't you fin tease us
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 27 at 3:14 AM
$COGT better days ahead please
0 · Reply
Eagley3k
Eagley3k Oct. 25 at 6:27 PM
$COGT we have been waiting for long. When are we gonna get paid bruh?
1 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 24 at 4:38 PM
$COGT so press release of KRAS poster presentation today. Thought it would be a slam dunk poster like Vince Carter over the European guy. Well, kind of is ..cause we're the European guy.
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 24 at 11:41 AM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 23 at 9:25 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 23 at 3:56 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 23 at 11:44 AM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 22 at 9:39 PM
$COGT show us something good Mr ceo
0 · Reply
Latest News on COGT
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 24, 2025, 12:30 PM EDT - 3 days ago

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

Oct 20, 2025, 8:32 AM EDT - 7 days ago

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 29, 2025, 4:05 PM EDT - 4 weeks ago

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:07 PM EDT - 7 weeks ago

Cogent Biosciences, Inc. (COGT) Presents At Citi's Biopharma Back To School Conference Transcript

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Aug 26, 2025, 8:00 AM EDT - 2 months ago

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 2 months ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 10, 2025, 4:01 PM EDT - 3 months ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results

Jul 9, 2025, 4:04 PM EDT - 3 months ago

Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Jul 8, 2025, 9:36 PM EDT - 3 months ago

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Jul 8, 2025, 4:26 PM EDT - 3 months ago

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Why Is Cogent Biosciences Stock Trading Higher On Monday?

Jul 7, 2025, 9:22 AM EDT - 4 months ago

Why Is Cogent Biosciences Stock Trading Higher On Monday?

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Jul 7, 2025, 7:06 AM EDT - 4 months ago

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Jun 11, 2025, 8:00 AM EDT - 4 months ago

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 5 months ago

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Cogent Biosciences Reports First Quarter 2025 Financial Results

May 6, 2025, 8:00 AM EDT - 6 months ago

Cogent Biosciences Reports First Quarter 2025 Financial Results

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Apr 25, 2025, 8:08 AM EDT - 6 months ago

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:31 PM EDT - 7 months ago

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Mar 7, 2025, 8:00 AM EST - 8 months ago

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Feb 27, 2025, 8:00 AM EST - 8 months ago

Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 8:00 AM EST - 8 months ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Feb 10, 2025, 9:15 AM EST - 9 months ago

Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 9 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN JAZZ ONC XBI ZYME

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Jan 18, 2025, 3:27 AM EST - 10 months ago

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Dec 9, 2024, 7:00 AM EST - 11 months ago

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Dec 8, 2024, 12:00 PM EST - 11 months ago

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Jun 14, 2024, 7:30 AM EDT - 1 year ago

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

May 23, 2024, 5:05 PM EDT - 1 year ago

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

May 23, 2024, 5:01 PM EDT - 1 year ago

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

Cogent Biosciences Reports First Quarter 2024 Financial Results

May 7, 2024, 8:00 AM EDT - 1 year ago

Cogent Biosciences Reports First Quarter 2024 Financial Results

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Apr 9, 2024, 9:00 AM EDT - 1 year ago

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Feb 22, 2024, 2:30 PM EST - 1 year ago

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Feb 14, 2024, 7:00 AM EST - 1 year ago

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Feb 5, 2024, 9:00 AM EST - 1 year ago

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Jan 9, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 8:00 AM EST - 1 year ago

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment

Dec 11, 2023, 8:23 AM EST - 2 years ago

Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Dec 11, 2023, 7:55 AM EST - 2 years ago

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Dec 9, 2023, 1:30 PM EST - 2 years ago

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Dec 7, 2023, 9:00 AM EST - 2 years ago

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

Nov 29, 2023, 8:00 AM EST - 2 years ago

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor

Aug 15, 2023, 5:03 PM EDT - 2 years ago

Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

Jul 7, 2023, 11:23 AM EDT - 2 years ago

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

CRC IRWD

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

Jun 9, 2023, 4:01 PM EDT - 2 years ago

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference

Jun 7, 2023, 9:00 AM EDT - 2 years ago

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference

Cogent Biosciences Announces Proposed Public Offering of Common Stock

Jun 6, 2023, 4:05 PM EDT - 2 years ago

Cogent Biosciences Announces Proposed Public Offering of Common Stock

HahaYouSUCK
HahaYouSUCK Oct. 27 at 8:35 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 27 at 1:37 PM
$COGT don't you fin tease us
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 27 at 3:14 AM
$COGT better days ahead please
0 · Reply
Eagley3k
Eagley3k Oct. 25 at 6:27 PM
$COGT we have been waiting for long. When are we gonna get paid bruh?
1 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 24 at 4:38 PM
$COGT so press release of KRAS poster presentation today. Thought it would be a slam dunk poster like Vince Carter over the European guy. Well, kind of is ..cause we're the European guy.
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 24 at 11:41 AM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 23 at 9:25 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 23 at 3:56 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 23 at 11:44 AM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 22 at 9:39 PM
$COGT show us something good Mr ceo
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 22 at 9:04 PM
$COGT ty Mr tramp
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 22 at 6:38 PM
$COGT fin trump
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 22 at 12:30 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 21 at 8:19 PM
$COGT ty Mr President
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 21 at 2:36 PM
$COGT mfer jesus
0 · Reply
anachartanalyst
anachartanalyst Oct. 21 at 12:01 PM
$COGT https://anachart.com/wp-content/uploads/ana_temp/1761048093_soc-img.jpg
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 21 at 11:41 AM
$COGT
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 11:32 AM
JP Morgan updates rating for Cogent Biosciences ( $COGT ) to Overweight, target set at 30 → 44.
0 · Reply
Alloptionsn
Alloptionsn Oct. 21 at 1:27 AM
$COGT can anyone speculate as to why this hasn’t moved in light of the news below?
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 20 at 9:40 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 20 at 8:51 PM
$COGT
0 · Reply
HahaYouSUCK
HahaYouSUCK Oct. 20 at 8:15 PM
$COGT as a graduate of DeVry a University with a BS in medical assistance, calculating the possibility of positive results from APEX and PEAK is extremely high p<00.5.
0 · Reply